Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Department of Pediatric Haematology and Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Acta Oncol. 2021 May;60(5):658-666. doi: 10.1080/0284186X.2021.1881817. Epub 2021 Mar 12.
Pediatric Hodgkin lymphoma (pHL) is highly curable. However, a minority experience relapse and are subjected to toxic salvage regimens. Investigating the patterns of relapse could help to select the patients and/or the involved sites that would benefit from consolidating radiotherapy.
The Danish Childhood Cancer Registry was used to identify children <18 years with relapsed pHL from 1990-2018. The lymphoma volumes involved at diagnosis and at relapse were contoured on the patients' original scans. Rigid image co-registration was used to merge the scans enabling a visual assessment of the anatomical relapse localization relative to the initially involved lymph nodes, and if irradiated, to the radiotherapy field.
From 185 patients with pHL, 24 patients with relapse were available for analysis. All patients received combination chemotherapy and seven had consolidating radiotherapy. Relapses exclusively in initially involved sites occurred in 14 patients. Relapses exclusively in new sites were rare and only observed in three irradiated patients. Seven patients relapsed in both initially involved and new sites. The median time to relapse was 6 months (range 2-59 months), however, in-field relapses in irradiated patients occurred later (54 months, range 10-59 months). Neither risk group, initial bulky disease, early response, or metabolic activity seemed to be associated with the site of a later relapse.
The number of relapses were small, and conclusions regarding the selection of patients for radiotherapy could not be drawn. Relapse exclusively in initially involved sites were the most common, most often in the exact same initially involved lymph nodes. Hence, modern involved site radiotherapy, focusing on the initially involved lymphoma volume and minimizing the radiation doses to normal tissues, should be applied when consolidating radiotherapy is used in patients with pHL.
儿科霍奇金淋巴瘤(pHL)的治愈率很高。然而,仍有少数患者会复发,并接受毒性较大的挽救性治疗方案。研究复发模式有助于选择需要接受巩固性放疗的患者和/或受累部位。
利用丹麦儿童癌症登记处,从 1990 年至 2018 年,确定了 18 岁以下复发的 pHL 患儿。在患者的原始扫描图像上勾画出诊断时和复发时涉及的淋巴瘤体积。采用刚性图像配准技术,将扫描图像融合,以评估解剖学复发部位与最初受累淋巴结的相对位置,以及是否与放疗野相关。
在 185 例 pHL 患儿中,有 24 例复发患儿可用于分析。所有患者均接受联合化疗,7 例患者接受巩固性放疗。14 例患者仅在最初受累部位复发。新部位复发罕见,仅在 3 例接受放疗的患者中观察到。7 例患者在最初受累和新部位均有复发。中位复发时间为 6 个月(范围 2-59 个月),但在接受放疗的患者中,瘤床复发时间较晚(54 个月,范围 10-59 个月)。风险组、初始巨大肿块、早期反应或代谢活性均与复发部位无明显相关性。
复发例数较少,无法得出关于放疗患者选择的结论。最初受累部位的复发最常见,通常在最初受累的淋巴结中。因此,在 pHL 患者中使用巩固性放疗时,应采用现代受累部位放疗,重点关注最初受累的淋巴瘤体积,并尽量减少正常组织的辐射剂量。